Skip to main content

Table 1 Patient characteristics and number of genomic alterations detected in ctDNA among pancreatic ductal adenocarcinoma patients (N = 112)

From: Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer

Characteristics for all patients [N = 112]N (%)
 Median age (range) (years)*67.8 (38.0–92.7)
  Men60 (53.6%)
  Women52 (46.4%)
  Caucasian76 (67.9%)
  Hispanic16 (14.3%)
  Asian7 (6.3%)
  African American4 (3.6%)
  Other/unknown9 (8.0%)
 Disease status at the time of blood draw 
  Advanced (metastatic, locally advanced or recurrent disease)94 (83.9%)
  Preoperative (surgically resectable, blood obtained before surgery)10 (8.9%)
  Postoperative (surgically resectable, blood obtained after surgery)8 (7.1%)
 Number of patients with ≥ 1 characterized alteration78 (69.6%)
 Median number of characterized alterations per patient (range)1 (0–6)
Comparisons of ctDNA results between advanced cases and preoperative cases**
ParametersAdvanced cases (N = 94)Preoperative cases (N = 10)P value
Number of characterized alterations per patient (range), median (range) (%)2 (0–6)0.5 (0–3)0.04
No. of patients with detectable characterized alterations70 (74.5%)5 (50.0%)0.14
Maximum %ctDNA per patient (characterized alterations), median (range) (%)0.4 (0.0–64.6)0.0 (0.0–0.62)0.02
Total %ctDNA per patient (characterized alterations), median (range) (%)0.6 (0.0 - 92.05)0.0 (0.0 - 0.70)0.007
  1. *Age at date of advanced disease diagnosis or date of first diagnosis for surgically resectable diseases
  2. **Postoperative cases (blood obtained after radical surgery) were not included in these comparisons